Key Drivers
- Positive FCF
- High leverage
- Large intangibles
AIAI Summary
Perrigo should be reclassified from a defensive OTC cash‑cow to a stressed, operable turnaround whose investment case now hinges directly on timely realization of $230–$300M+ run‑rate savings and closing divestitures to materially reduce $3.64B of debt — if management delivers consecutive quarters showing realized run‑rate savings and announced divestiture proceeds dedicated to debt paydown, the stock can re-rate; if savings slip, proceeds are delayed, impairments occur, or litigation drains cash, downside will accelerate.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Positive FCF
- •High leverage
- •Large intangibles
PRGO generates solid gross margins and positive free cash flow but faces large operating losses, heavy debt and big intangible exposure that undermine profitability and make the dividend/payout strategy risky.
Price Behavior
Key Price Behavior Insights:
- •Oversold momentum
- •Below last month SMA
- •Failure/hold pivot
PRGO is in a short-term downtrend—trading around $9.25 well below its last-month SMA (~$11.39) with an RSI ≈23 suggesting a possible short-term bounce but a reclaim of ~$11.39 and the Feb resistance band ~$14.20–$14.80 is needed to reverse while a break below $9.25–$9.30 would confirm further downside.
Rapid retracement from
Sentiment & News
Key News Insights:
- •Q4 earnings miss
- •Infant Formula pressure
- •$80–$100M savings plan
Perrigo missed Q4 EPS and saw organic sales decline amid Infant Formula headwinds, but launched a cost-savings program, will change reporting segments, and drew analyst/institutional interest.
Short-term earnings and organic-sales pressure likely weigh on the stock, but operational savings, reporting clarity and renewed institutional buying could support a recovery over the next 12–18 months
Similar Companies in Healthcare
Other companies in the same sector with AI ratings